Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. - Wikidata - awgldk - TriplyDB

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

http://www.wikidata.org/entity/Q33201555

about

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Lipid posttranslational modifications. Farnesyl transferase inhibitors.

P2860

Q33914284-D56CCDF7-FD67-4949-8076-516DE2CDE12D Q34651253-0B9BA752-0466-426F-B1AE-E6C95A133F5C

P2860

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

http://www.wikidata.org/entity/Q33201555

description

2004 nî lūn-bûn

@nan

2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@ast

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@en

type

label

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@ast

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@en

prefLabel

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@ast

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@en

P1433

Q33201555-34B060BD-9D95-4460-9F12-34932C993EF2

P1476

Q33201555-6F8242A1-2B46-43DD-BBDA-4684F425C3EA

P2093

Q33201555-15153C58-E260-4FC4-BF6F-117C1408C3D8

Q33201555-208E1234-A28D-4D79-B14E-E0BA782606CB

Q33201555-28F429A6-FB34-416F-A72B-7D33D344F7A2

Q33201555-5F78A321-5E3E-4C9C-BD81-2663BD03057C

Q33201555-613DAE95-D60A-4304-AFC4-BC9AF441D1F1

Q33201555-6FCD9672-84D6-4FBB-B253-2D5498CA31A4

Q33201555-7140CDC3-FB7D-40EB-AC21-2325C6D188F9

Q33201555-9315B2FD-406D-42E0-8654-BE60532399A9

Q33201555-D3881FCF-4BE3-4161-BE4C-6E99D83488B4

Q33201555-DD1E15E4-473E-4694-876D-74E7AC5972FF

P2860

Q33201555-0353F983-324E-4D29-9942-C2D69A5E347E

Q33201555-0513653C-489C-4E7A-9379-BB42D9FC1EE5

Q33201555-11FE5773-181C-4438-A2F7-0055C46057DB

Q33201555-25C384EC-EB58-4E79-AC64-BD6FC694238E

Q33201555-272BF5EA-B49C-46ED-B465-A3C50BF80F37

Q33201555-2930B4D5-0B29-4219-BBCF-E19F180636FD

Q33201555-36A28AB8-2313-4E67-AEA4-AF9ED6FF3334

Q33201555-38657931-648A-43C6-B4CA-BCEB83B08D75

Q33201555-3E2F49E0-0AA5-44CB-B1C5-33EBA30F8A7C

Q33201555-3EF50513-14A4-4164-95EB-C18D3F784438

P2888

Q33201555-3977B24C-1AE0-4461-9354-7F37955256C1

P304

Q33201555-D68192A0-0F9C-4056-B873-D169BF99C903

P31

Q33201555-204CCBF9-F668-47AB-B53F-BBDD187027F2

P356

Q33201555-D2680D5C-E001-4E36-92E8-D5AD3E3C1216

P407

Q33201555-CFDF2541-8056-4CFB-9DAC-D6BF1745150C

P433

Q33201555-AC011D56-EEBB-43B7-BC33-22B1B946731B

P478

Q33201555-1740BB83-50EC-402F-84F1-8248A2E81C16

P577

Q33201555-978351A9-B1A9-4854-838F-29B30D677005

P5875

Q33201555-ECC48ACE-A6B7-44A6-9210-EC912CE4DFAB

P6179

Q33201555-92BA5AA7-6FAB-49BE-8A28-1A070A3E1DA3

P698

Q33201555-2A65DB3A-BC41-4657-8898-BA6BDE7C8D64

P932

Q33201555-5BAF2EC2-37DF-43D2-8A12-957F2EDE55FA

P356

P1433

British Journal of Cancer

P1476

Phase I and pharmacokinetic st ...... protein transferase inhibitor.

@en

P2093

A Klaren

http://www.w3.org/2001/XMLSchema#string

A S T Planting

http://www.w3.org/2001/XMLSchema#string

A Sparreboom

http://www.w3.org/2001/XMLSchema#string

C Verheij

http://www.w3.org/2001/XMLSchema#string

D F S Kehrer

http://www.w3.org/2001/XMLSchema#string

F A L M Eskens

http://www.w3.org/2001/XMLSchema#string

G de Heus

http://www.w3.org/2001/XMLSchema#string

J Verweij

http://www.w3.org/2001/XMLSchema#string

M J A de Jonge

http://www.w3.org/2001/XMLSchema#string

P A Palmer

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Modulation of irinotecan metabolism by ketoconazole.

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

Blocking oncogenic Ras signaling for cancer therapy.

Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer.

Role of genomics in identifying new targets for cancer therapy.

Individualized cancer therapy: molecular approaches to the prediction of tumor response.

P2888

P304

1508-1515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601732

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232801226

http://www.w3.org/2001/XMLSchema#string

P6179

1050009406

http://www.w3.org/2001/XMLSchema#string

P698

15083177

http://www.w3.org/2001/XMLSchema#string

P932

2409716

http://www.w3.org/2001/XMLSchema#string